Gathering and analyzing patient experience data in a real-world setting is a key challenge for many

By HEOR Staff Writer

January 18, 2023

Gathering and analyzing patient experience data in a real-world setting is a key challenge for many. To explore this further, ISPOR in Vienna held a second plenary panel featuring experts in the field. What did they discuss?

The panel discussed the importance of rigor in choosing, implementing, and analyzing patient experience data in non-randomized, uncontrolled study designs. Dr. Burgos spoke about the Darwin EU initiative and the importance of stakeholder engagement and capacity building to facilitate patient experience data collection. Professor Devlin discussed the implementation of patient-reported outcome data capture and the PROMs initiatives in the UK, Canada, and New Zealand. Dr. Perfetto spoke about the Core Impact initiative in the US, which standardizes patient experience data collection and the use of core outcome sets.

The panel highlighted the need for further guidance and collaboration with stakeholders to ensure patient experience data is used to inform regulatory decision-making.

Reference url

Recent Posts

Enhancing Efficiency in FAST-EU Clinical Trials: A New Era for Biomedical Research

By João L. Carapinha

December 1, 2025

Advancing EU Clinical Trial Efficiency Through FAST-EU Trials The FAST-EU clinical trials initiative, launched by a coalition of National Competent Authorities (NCAs) and Ethics Committees across the European Union/Europ...
GLP-1RAs Psychiatric Care: Transforming Metabolic Management for Psychotropic Patients

By HEOR Staff Writer

November 27, 2025

Emerging Role of GLP-1 Receptor Agonists In psychiatric care, GLP-1RAs offer a promising approach for managing weight gain induced by psychotropic medications, as detailed in this
NICE Endorses Obecabtagene Autoleucel Therapy for Adult Relapsed B-Cell Leukaemia

By João L. Carapinha

November 25, 2025

NICE Backs Obecabtagene Autoleucel The National Institute for Health and Care Excellence (NICE) recommended obecabtagene autoleucel therapy, a UK-developed chimeric antigen receptor (CAR) T-cell trea...